Symbols

LYEL

Lyell Immunopharma·NASDAQ

--(--)

LYEL Profile

Lyell Immunopharma, Inc.

A clinical‑stage T-cell reprogramming company that develops curative cell therapies for solid tumors

Industry

Biological Technology

Established Date

06/29/2018

Listing Date

06/17/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

161

Fiscal Year Ends

12-31

Website

www.lyell.com

Security Type

Common stock

Office address

201 Haskins Way, South San Francisco, California 94080

Business

Introduction

Lyell Immunopharma, Inc., was incorporated in Delaware on June 29, 2018. The Company is a late-stage clinical cell therapy company that is advancing a proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidate for cancer patients. The company's goal is to realize the full therapeutic potential of cell therapy for patients with hematological malignancies and solid tumors. To achieve this goal, the company is pioneering new approaches aimed at generating T-cell therapies to drive durable clinical responses. The company's CAR T cell product candidates start by identifying promising cancer targets. The company then designs the patient's own living immune cells and provides them with innovative enhancements, including CAR construction, technology and manufacturing protocols designed to give T cells a stronger cancer-killing ability.